Smart-Money SignalDistribution · 42/100— Insiders are net sellers over 90 days (-$9.5M, 27 sales vs 8 buys)
Revenue$7.0B
Net Income$2.0B
EPS$1.61
Market Cap$166.8B
Price Performance
Historical data including institutional events
Company Profile
D
Daniel O'Day
CEO & Executive Director
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
